| 101 |
14960504 | Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). | 2004 Feb 28 |
2 |
| 102 |
15025845 | Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE? | 2004 Mar |
1 |
| 103 |
15191027 | Fresh frozen plasma in the treatment of resistant angiotensin-converting enzyme inhibitor angioedema. | 2004 May |
1 |
| 104 |
15222408 | Hemodynamic effects of the angiotensin-converting enzyme inhibitor, ramipril, in patients with mild to moderate aortic stenosis and preserved left ventricular function. | 2004 Apr |
1 |
| 105 |
15257162 | Old antihypertensives and new diabetes. | 2004 Aug |
1 |
| 106 |
15353497 | Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction. | 2004 Sep 14 |
1 |
| 107 |
15389235 | Extended follow-up of patients randomly assigned in the Angiotensin-converting enzyme inhibition Post-Revascularization Study (APRES). | 2004 Sep |
1 |
| 108 |
15449961 | Cost effectiveness of ramipril in patients at high risk for cardiovascular events : economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective. | 2004 |
1 |
| 109 |
15485399 | The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes. | 2004 Nov |
1 |
| 110 |
15485427 | Proteinuria predicting outcome in renal disease: nondiabetic nephropathies (REIN). | 2004 Nov |
1 |
| 111 |
12615747 | The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario. | 2003 Mar 4 |
2 |
| 112 |
12628949 | Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. | 2003 Mar 11 |
2 |
| 113 |
12639174 | Ramipril for the prevention and treatment of cardiovascular disease. | 2003 Mar |
3 |
| 114 |
12671332 | The African American Study of Kidney Disease and Hypertension (AASK) trial: what more have we learned? | 2003 Mar-Apr |
1 |
| 115 |
12694342 | Cardiovascular risk in patients with mild renal insufficiency. | 2003 May |
1 |
| 116 |
12708937 | HOPE study impact on ACE inhibitors use. | 2003 May |
2 |
| 117 |
12729847 | Prevention and management of chronic heart failure in patients at risk. | 2003 May 8 |
1 |
| 118 |
12809971 | Assessment of the effect of ramipril therapy on direct health care costs for first and recurrent strokes in high-risk cardiovascular patients using data from the Heart Outcomes Prevention Evaluation (HOPE) study. | 2003 Apr |
2 |
| 119 |
12819323 | The rationale and design of the AASK cohort study. | 2003 Jul |
1 |
| 120 |
12859160 | Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. | 2003 Jul 15 |
3 |
| 121 |
12911540 | Mast cell infiltration and chemokine expression in progressive renal disease. | 2003 Sep |
1 |
| 122 |
12968195 | Evolving rationale for angiotensin-converting enzyme inhibition in chronic heart failure. | 2003 Sep |
1 |
| 123 |
13677258 | [The status of atherosclerosis prevention in Austria]. | 2003 |
2 |
| 124 |
14567371 | Synergy between publication and promotion: comparing adoption of new evidence in Canada and the United States. | 2003 Oct 15 |
1 |
| 125 |
14625162 | Recommendations for the management of special populations: racial and ethnic populations. | 2003 Nov |
1 |
| 126 |
15107595 | Cardiovascular drugs and serum uric acid. | 2003 Sep-Nov |
2 |
| 127 |
11804984 | Comparative effects of estrogen and angiotensin-converting enzyme inhibition on plasminogen activator inhibitor-1 in healthy postmenopausal women. | 2002 Jan 22 |
1 |
| 128 |
11835905 | Angiotensin II and trials of cardiovascular outcomes. | 2002 Jan 24 |
1 |
| 129 |
11835907 | From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. | 2002 Jan 24 |
2 |
| 130 |
11843949 | Attenuating CV risk factors in patients with diabetes: clinical evidence to clinical practice. | 2002 Jan |
1 |
| 131 |
11843951 | What should the role of ACE inhibitors be in the treatment of diabetes? Lessons from HOPE and MICRO-HOPE. | 2002 Jan |
1 |
| 132 |
11843952 | Reducing the risk of stroke in diabetes: what have we learned that is new? | 2002 Jan |
1 |
| 133 |
11903350 | A prospective evaluation of the angiotensin-converting enzyme D/I polymorphism and left ventricular remodeling in the 'Healing and Early Afterload Reducing Therapy' study. | 2002 Jan |
1 |
| 134 |
11986905 | Blockade of endothelial enzymes: new therapeutic targets. | 2002 Mar |
2 |
| 135 |
12025972 | ACE inhibition and atherogenesis. | 2002 Apr |
2 |
| 136 |
12076194 | Ramipril: a review of its use in the prevention of cardiovascular outcomes. | 2002 |
2 |
| 137 |
12143014 | [Parvovirus B19 myocarditis in a young man with previous non-bacterial meningitis]. | 2002 Jul 26 |
1 |
| 138 |
12204499 | Effect of long-term therapy with ramipril in high-risk women. | 2002 Aug 21 |
2 |
| 139 |
12324991 | Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. | 2002 Sep-Oct |
1 |
| 140 |
12423701 | Impact of ramipril versus other angiotensin-converting enzyme inhibitors on outcome of unselected patients with ST-elevation acute myocardial infarction. | 2002 Nov 15 |
2 |
| 141 |
14727978 | Cardiovascular risk in patients with early renal insufficiency: implications for the use of ACE inhibitors. | 2002 |
1 |
| 142 |
11276395 | Recent clinical trial highlights in hypertension. | 2001 Apr |
1 |
| 143 |
11343399 | Ask the doctor. Recently, I read that the ACE inhibitor ramipril is very good at preventing heart problems, particularly in people with diabetes. I'm diabetic, and for years I have been on a different ACE inhibitor (lisinopril). Should I be taking ramipril instead? | 2001 Apr |
1 |
| 144 |
11347755 | Reduction of ACE activity is insufficient to decrease microalbuminuria in normotensive patients with type 1 diabetes. | 2001 May |
1 |
| 145 |
11381289 | Why were the results of the Heart Outcomes Prevention Evaluation (HOPE) trial so astounding? | 2001 May |
2 |
| 146 |
11446026 | [Decreased platelet aggregation during angiotensin-converting enzyme inhibitor therapy. Results of a pilot study]. | 2001 Jun 15 |
2 |
| 147 |
11465309 | Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance. | 2001 |
1 |
| 148 |
11479247 | Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study. | 2001 Jul 31 |
1 |
| 149 |
11496052 | The Heart Outcomes Prevention Evaluation study: angiotensin-converting enzyme inhibitors: are their benefits a class effect or do individual agents differ? | 2001 Sep |
2 |
| 150 |
11581138 | Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. | 2001 Oct 2 |
2 |